Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Larimar Therapeutics Inc.

    NASDAQ: LRMR · Real-Time Price · USD
    2.96
    -0.12 (-3.90%)
    At close: Jun 27, 2025, 11:15 AM

    Larimar Therapeutics Statistics

    Share Statistics

    Larimar Therapeutics has 64.03M shares outstanding. The number of shares has increased by 0.35% in one year.

    Shares Outstanding

    n/a
    		 64.03M

    Shares Change (YoY)

    n/a
    		 0.35%

    Shares Change (QoQ)

    n/a
    		 0.35%

    Owned by Institutions (%)

    n/a
    		 99.42%

    Shares Floating

    n/a
    		 36.46M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,739

    FTD / Avg. Volume

    n/a
    		 0.13%

    Short Selling Information

    The latest short interest is 6.37M, so 9.95% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.37M

    Short % of Shares Out

    n/a
    		 9.95%

    Short % of Float

    n/a
    		 18.02%

    Short Ratio (days to cover)

    n/a
    		 5.72

    Valuation Ratios

    The PE ratio is -2.94 and the forward PE ratio is -1.64. Larimar Therapeutics's PEG ratio is -0.05.

    PE Ratio

    n/a
    		 -2.94

    Forward PE

    n/a
    		 -1.64

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.5

    PB Ratio

    n/a
    		 1.38

    P/FCF Ratio

    n/a
    		 -3.33

    PEG Ratio

    n/a
    		 -0.05
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Larimar Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.02, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 8.02

    Quick Ratio

    n/a
    		 8.02

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.06

    Debt / FCF

    n/a
    		 -0.07

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,240,061.54

    Employee Count

    n/a
    		 65

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -58.1% in the last 52 weeks. The beta is 0.79, so Larimar Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.79

    52-Week Price Change

    n/a
    		 -58.1%

    50-Day Moving Average

    n/a
    		 2.37

    200-Day Moving Average

    n/a
    		 4.3

    Relative Strength Index (RSI)

    n/a
    		 60.95

    Average Volume (20 Days)

    n/a
    		 1,294,312

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -90.89M

    Net Income

    n/a
    		 -80.6M

    EBITDA

    n/a
    		 -80.29M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -1.32
    Full Income Statement

    Balance Sheet

    The company has 33.22M in cash and 5.12M in debt, giving a net cash position of 28.1M.

    Cash & Cash Equivalents

    n/a
    		 33.22M

    Total Debt

    n/a
    		 5.12M

    Net Cash

    n/a
    		 28.1M

    Retained Earnings

    n/a
    		 -269.16M

    Total Assets

    n/a
    		 170.18M

    Working Capital

    n/a
    		 143.35M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -70.76M and capital expenditures -515K, giving a free cash flow of -71.28M.

    Operating Cash Flow

    n/a
    		 -70.76M

    Capital Expenditures

    n/a
    		 -515K

    Free Cash Flow

    n/a
    		 -71.28M

    FCF Per Share

    n/a
    		 -1.16
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    LRMR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for LRMR is $16, which is 419.5% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $16

    Price Target Difference

    n/a
    		 419.5%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 29, 2020. It was a backward split with a ratio of 1:12.

    Last Split Date

    n/a
    		 May 29, 2020

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:12

    Scores

    Altman Z-Score

    n/a
    		 -0.3

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist